Stellar stock: buy or sell?

SBOT stock price: $298,098.00 7.00% At close on June 28th, 2019

Updated on:
June 28th, 2019

5

Stellar Biotechnologies shares crossed up the SMA line of 200d today and closed at $298,098.00. On June SBOT plunged a scary -26.83%.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia.

Should I buy Stellar stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Stellar stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean SBOT will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Stellar Biotechnologies stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for SBOT stock for the last month.

Stellar stock analysis

Daily outlook

Stellar Biotechnologies shares crossed up the SMA line of 200d today and closed at $298,098.00.

Stellar Biotechnologies broke up the simple moving average line of 200 days today and closed at $298,098.00. Since SMA100d and SMA200d crossed up on June, SBOT price climbed $298,092.80 per share (5,732,553.85%). From a daily perspective, SBOT is in a short term uptrend after plotting its last bottom ($1.03, on June) higher than the previous bottom, and its last top ($6.18, on June) also over the previous top. Now trading in between its last bottom and last top SBOT might consolidate in a plain range, waiting to break out over $6.18 or down under $1.03.

SBOT stock chart (daily)

Weekly outlook

Stellar Biotechnologies crossed up the simple moving average line of 200d, closing at $298,098.00. Early June SBOT plummed a spooky -85.71% in just one week.

Stellar Biotechnologies stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Late May, SMA20w and SMA40w crossed up triggering a rise of 26,615,792.86%.

SBOT stock chart (weekly)

Stellar stock price history

Stellar stock went public on September 10th, 2010 with a price of $28.001. Since then, SBOT stock surged a 1,064,535.70%, with an average of 133,067.00% per year. If you had invested $1,000 in Stellar stock in 2010, it would worth $10,645,357.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Stellar stock historical price chart

SBOT stock reached 52-week highs on June at $6.18, and all-time highs 2014-08-28 with a price of 165.2.

Stellar stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' SBOT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price target for Stellar stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Stellar presented its financial report, posting a pretty good growth for the Earnings per Share (EPS). Analyst expected $-0.23 per share, but Stellar Biotechnologies posted $-0.26.
SBOT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.11n/a
2017-Q2-n/a-0.12n/a
2017-Q32017-12-01-0.11n/an/a
2017-Q42018-02-08n/an/an/a
2018-Q12018-07-03n/an/an/a
2018-Q22018-08-08-0.45-0.38n/a
2018-Q32019-01-04n/an/an/a
2018-Q42019-02-05-0.23-0.26n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Stellar annual turnover fell a rough -7.20% to $0.21 M USD from $0.23 marked in 2017. In contrast, its earnings margin (compared to sales) plunged to -2,378.56%, that is $-5.04 million.

Stellar Biotechnologies fiscal year ends in September, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Stellar Biotechnologies TTM sales up to December 2018 were $0.24 and earnings $-5.04 M dollars. When comparing this TTM figures with the last reported annuality, we can review Stellar Biotechnologies business evolution since September 2018: Annual sales up to December, compared to lastest yearly report, rocketed an extraordinary 15.36%. Regarding profit margin, Stellar Biotechnologies climbed 314.73% to -2,378.56%

SBOT annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$0.55 M-$-14.89 M-2729.8%-
2014$0.05 M-90.32%$1.13 M2136.7%-107.57%
2015$0.76 M1,337.29%$-2.84 M-374.7%-352.06%
2016$1.27 M67.62%$-5.03 M-395.2%76.79%
2017$0.23 M-82.05%$-5.03 M-2203.7%0.09%
2018$0.21 M-7.20%$-5.04 M-2378.6%0.16%
TTM $0.24 M15.36%$-5.04 M-2063.8%0.10%

Quarterly financial results

Stellar Biotechnologies reported $0.05 M in sales for 2018-Q4, a -2.26% less compared to previous quarter. Reported quarter earnings marked $-1.41 million with a profit margin of -2,650.61%. Profit margin collapsed a -569.78% compared to previous quarter when profit margin was -2,080.84%. When comparing revenues to same quarter last year, Stellar sales marked a dazzling gain and climbed a 158.86%. Looking back to recent quarterly results, Stellar posted 2 negative quarters in a row.
SBOT quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$0.06 M-$-1.10 M-1745.5%-
2017-Q2$0.02 M-67.42%$-1.22 M-5941.9%10.91%
2017-Q3$0.00 M-85.97%$-1.22 M-42393.7%0.08%
2017-Q4$0.02 M611.35%$-1.40 M-6837.3%14.73%
2018-Q1$0.06 M212.65%$-1.35 M-2111.6%-3.44%
2018-Q2$0.07 M14.05%$-1.16 M-1583.3%-14.48%
2018-Q3$0.05 M-25.73%$-1.13 M-2080.8%-2.39%
2018-Q4$0.05 M-2.26%$-1.41 M-2650.6%24.51%

Stellar ownership

When you are planning to buy a stock, it's always worth to check its ownership structure.

Stellar shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

The following table compares ownership indicators for other stocks related to Stellar:

SBOT
Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

Stellar summary

Friday, June 28th, 2019
Open$1.11
Close$298098.00
Day range$1.03 - $1.17
Previous close$3.97
Session gain7,508,665.74%
Average true range$1.00
50d mov avg$5,963.35
100d mov avg$2,982.27
200d mov avg$1,491.72
Daily patternlt06a
Weekly pattern lt06a

Stellar performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Stellar Biotechnologies against in the following table:
Stock3m6m12m
SBOTStellar Biotechno...25921500.00%33494100.00%16200900.00%

Stellar competitors

Unfortunately, we could not find any public company that could be defined as Stellar competitor. This doesn't mean Stellar does not have any competitor in the market, it's just we could not detected it.